Canada’s Drug Agency (CDA-AMC) recommends that Rybrevant should be reimbursed by public drug plans when used in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) with activating EGFR exon 20 insertion (ex20ins) mutations if certain conditions are met.
